Oxyresveratrol and its synthetic derivatives on the stimulation of glucose uptake in skeletal muscle cells and the activation of AMPK

Tharita Kitisripanya\textsuperscript{a}, Hathairat Buraphaka\textsuperscript{b}, Panitch Boonsnongcheep\textsuperscript{c}, Boonchoo Sritularak\textsuperscript{d}, Kittisak Likhitwitayawuid\textsuperscript{d}, Waraporn Patalun\textsuperscript{b,∗}

\textsuperscript{a} Faculty of Pharmacy, Mahidol University, Bangkok 10400 Thailand
\textsuperscript{b} Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002 Thailand
\textsuperscript{c} Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170 Thailand
\textsuperscript{d} Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 1033 Thailand

∗Corresponding author, e-mail: waraporn@kku.ac.th

Received 28 Mar 2021
Accepted 22 Sep 2021

ABSTRACT: Diabetes mellitus (DM) is a hyperglycemic condition occurring due to insulin resistance or impaired insulin secretion. Structural modifications of natural products are a promising way to discover new lead compounds for DM management. Oxyresveratrol, abundantly found in \textit{Artocarpus lacucha} Buch. - Ham. heartwood and \textit{Morus alba} L. wood, exhibited biological activities against metabolic syndromes associated with diseases including DM. Hence, in this study, oxyresveratrol was used as the precursor for its synthetic derivatives. Then, the compound and its nineteen derivatives were investigated for their glucose uptake activities in L6 rat skeletal muscle cells. The results showed that oxyresveratrol and its derivative, 5-carboxy-2,3′,4,5′-tetrahydroxystilbene, possess a higher glucose uptake activity than metformin. They also elevated AMPK alpha-1 mRNA expression in a dose-dependent manner. Moreover, their binding energy against AMPK active sites was reported, and the finding would be applicable to further investigations of oxyresveratrol, including structure-activity relationship and structural modification.

KEYWORDS: oxyresveratrol, medicinal chemistry, glucose uptake, AMPK, molecular docking analysis

INTRODUCTION

Diabetes mellitus (DM) is a hyperglycemic condition occurring due to insulin resistance or impaired insulin secretion. One of the pathological causes of DM was developed from metabolic syndromes which are associated with hypertension, hyperglycemia, high belly fat accumulation, and abnormality of cholesterol and triglyceride levels in blood circulation. These conditions lead to complications in DM patients, e.g., cardiovascular disease, ischemic stroke, life-threatening severe renal failure [1]. Hence, the therapeutic approach based on the mechanism involving metabolic syndromes would be the prevention or treatment intervention of DM.

The AMP-activated protein kinase (AMPK) is an alpha-beta-gamma (α-β-γ) heterotrimer found in various cell types. It plays an essential role in regulating whole-body glucose homeostasis. In recent years, AMPK activators, based on theirs reported actions in the liver and the skeletal muscle, have been known as a promising pharmacological target for the prevention and the treatment of type 2 DM and metabolic diseases [2, 3]. The catalytic subunit of the AMPK, including the AMPK α1 and the AMPK α2 sub-types, is the α subunit. While the AMPK α1 is generally distributed in the body, the AMPK α2 is highly expressed in heart, liver, and skeletal muscles. In the skeletal muscles, the AMPK α2 sub-type constitutes more than half of the total AMPK α sub-type [4]. This implies that the AMPK α2 plays an essential metabolic role in the skeletal muscles. Both the AMPK α1 and the AMPK α2 sub-types are critical regulators of glucose metabolism with different functions. In DM patients, there is a malfunction of glucose uptake in skeletal muscle cells and adipocytes. Therefore, investigations of natural products possessing glucose uptake activity as potential agents could be applied for the prevention or the relief of insulin resistance. Besides, the knowledge of phytochemicals profiles in plant species could be a strategy to find the potential sources of active compounds against DM [5]. Several compounds including metformin [6], polyphenols (such as resveratrol) [7], quercetin [8], and ros-
marinic acid [9] are also recognized for activating AMPK and increasing muscle glucose uptake.

Oxyresveratrol (trans-2, 3', 4, 5'-tetrahydroxystilbene) is a natural stilbenoid isolated from Arto-
carpus lacucha Buch. - Ham. heartwood and abund-
antly found in mulberry wood (Morus alba L.). It
has parallel biological effects of resveratrol, which
include anti-oxidative, antiviral, anti-inflammatory,
and neuroprotective activities [10–15]. Besides,
the effects of oxyresveratrol on mechanisms associ-
ated with metabolic syndromes have been recently
investigated, for example, the alpha glucosidase
inhibitory activity [16], the amelioration of obesity-
associated symptoms [17], the hepatoprotective
function in non-alcoholic fatty liver disease [18],
the prevention of obesity, and the improvement
of glucose metabolism [19, 20]. To determine the
potential of oxyresveratrol and its synthetic deriva-
tives, their effects on glucose uptake activity (which
is associated with anti-diabetic activity) in skeletal
muscle cells were investigated. Consequently, high
potent compounds were selected for AMPK expres-
sion. In addition, to explore the structure-activity
relationship of the oxyresveratrol and its derivatives
on AMPK, their simulated binding energies were
investigated using molecular docking analysis. The
results from these investigations could be applied
for further structural modification of oxyresveratrol
as a potential anti-diabetic agent for DM therapy.

**MATERIALS AND METHODS**

Chemicals. α-MEM, fetal bovine serum (FBS),
and penicillin-streptomycin (10 000 IU/ml) were
purchased from Thermo Fisher Scientific (Grand
Island, NY, USA). Glucose (GO) assay kit, sodium
dodecyl sulfate (SDS), metformin, and 3-(4, 5–
dimethyl thiazol–2–yl)–5–diphenyl tetrazolium bro-
mide (MTT) were obtained from Sigma Aldrich
(St. Louis, MO, USA). Insulin (100 IU/ml) was
obtained from Biocon (Bangalore, India). All other
chemicals used were of analytical grade.

**PREPARATION OF THE SYNTHETIC
DERIVATIVES**

Oxyresveratrol was isolated from heartwood of Arto-
carpus lacucha Buch. - Ham. as previously de-
scribed [13]. Nineteen derivatives of oxyresveratrol
were synthesized based on the earlier method [16]
using oxyresveratrol as a precursor. O-alkylation,
acylation, halogenation, and aromatic electrophilic
substitution were used as the synthetic strategies for
preparation of oxyresveratrol derivatives. For exam-
ple, in O-alkylation, oxyresveratrol was allowed to
react with methyl iodide in acetonitrile at room tem-
perature to obtain di-, and tetra-O-methylated as O2
and O4, respectively. The alkylation of oxyresver-
atrool with 2-bromopropane/K2CO3 in DMF gave
the corresponding di-, tri-, and tetra-O-isopropyl
compounds as O5, O6, and O7, respectively. The
chemical structures of oxyresveratrol and the syn-
thetic derivatives are shown in Fig. 1.

**Cell lines and culture medium.** L6 (rat skeletal
muscle, ATCC® CRL-1458) cell culture was pur-
bought from the American Type Culture Collection
(Manassas, VA, USA). Stock cells of L6 were cultured
in a growth medium consisting of α-MEM, 10% FBS,
and 1% penicillin-streptomycin at 37 °C under 5%
CO2.

**Cytotoxicity.** The cytotoxicity test was per-
formed at 24 h after the cell treatment following Riss et al [21] with some modification. The medium
was adjusted to 200 µl per well. The cells were
treated with 20 µl MTT solution (5 mg/ml) and
incubated at 37 °C under 5% CO2 for 2 h. To dissolve
the formazan crystal, 200 µl solubilization solution
(40% DMF, 2% glacial acetic acid, and 16%w/v SDS
in distilled water) was added to each well, and the
well was shaken for 20 min. Then, the supernatants
were collected to measure the absorbance at 595 nm
using model 550 microplate reader (Biorad, Her-
cules, United States). The cytotoxicity was shown as the percentage of cell viability.

Glucose-uptake assay. The glucose-uptake assay was performed following Inthongkaew et al [22]. Briefly, rat L6 myoblasts were maintained in α-MEM supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C under 5% CO₂. The cells were then added in 24-well plates at a density of 2 × 10⁴ cells/well. Once the cells reached 90% confluence, the medium was switched to α-MEM with 2% FBS and 1% penicillin-streptomycin, the differentiated medium. The cells were allowed to differentiate into myotubes for 5–7 days, and the medium was changed every other day. After that, the myotubes were incubated at 37°C under 5% CO₂ for 24 h with various concentrations (1, 10 and 100 µg/ml) of oxyresveratrol and the nineteen derivatives. The positive controls were metformin (2 mM) and insulin (500 nM). The differentiated medium plus 0.1% DMSO was used as the diluent and the negative control. Then, the medium was collected, and the glucose level was determined using a glucose oxidase assay kit. The glucose uptake of test compounds was presented as the relative ratio over the percentage of glucose uptake of the negative control.

Expression levels of the AMPK α1 and the AMPK α2 affected by oxyresveratrol and its derivatives. Cells were culture in 24-well plates in a similar manner as previously described. After differentiation, they were treated with 1, 10, and 100 µg/ml oxyresveratrol and O24 for 24 h. Metformin (2 mM) and insulin (500 nM) were used as positive controls. The differentiated medium plus 0.1% DMSO was used as the diluent and the negative control. Then, the medium was removed and total RNA was extracted using TRIzol following the manufacturer’s protocol. The extracted RNA was converted to cDNA with the ReverTraAce Q PCR RT Master Mix (Toyobo, Osaka, Japan) following the recommended protocol. The real-time PCR analysis was performed using SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) following the manufacturer’s protocol. The real-time PCR analysis was performed using SYBR Green PCR Master Mix (Bio-Rad) in a CFX96 Real-Time PCR detection system (Bio-Rad). GADPH gene was used as a reference. Primers for amplification of the AMPK α1, the AMPK α2, and the GADPH are shown in Table S1. The PCR conditions were as follow: 3 min of 95°C initial denaturation; followed by 40 cycles of 20 s at 95°C, 20 s at 56°C, and 30 s at 72°C. Results are reported as the fold expression change relative to the control group. The experiments were conducted at least in triplicate. Experimental results were expressed as means ± standard deviations. Multiple group comparisons were performed with one-way ANOVA with Dunnett t-test at p < 0.05 using SPSS (version 17.0).

Docking analysis. The three-dimensional structure of AMPK was retrieved from Protein Data Bank (PDB code: 4CFE) and imported into the AutoDockTools (ADT, version 1.5.6). All water and hydrogen molecules were removed and added from the protein, respectively. The co-crystalline ligand, a benzimidazole derivative (991), was an AMPK activator and used as a reference compound [23]. The three-dimensional (3-D) structures of ligands were drawn using Chem3D Ultra 8.0, saved as pdb formats, and then changed into pdbqt formats by ADT. All water and hydrogen molecules were also removed and added from the ligands, respectively. Then, Gasteiger charges were computed. The receptor grid box for docking size was centered on the ligand in the active site on the α-2 subunit of the AMPK and set to 40, 40, 40 number of x-, y-, z-grid points and grid center at 476.564, 41.951, and 987.875 of x-, y-, and z-coordinates with a spacing of 0.375 Å using the AutoGrid 4.0. Each compound was docked inside a grid for ten conformations by AutoDock 4.0. Other docking parameters were set as default values [24]. The AutoDock docking runs were performed on an Intel® Core™ CPU i5-7200U 2.50 GHz processor with 4 GB RAM running Windows (Windows10, 64-bit) operating system. After molecular docking, the lowest binding energy of each ligand was selected and compared with the the 991 and the metformin.

RESULTS AND DISCUSSION
Cytotoxicity
After the exposure to oxyresveratrol and its derivatives at various concentrations of 1, 10 and 100 µg/ml, the percentage of cell viability in all treatments exhibited no cytotoxicity against L6 myotubes except O2, O5, O6, O10, O12, and O16 derivatives at a concentration of 100 µg/ml with less than 80% cell viability (Fig. 2A).

Glucose-uptake assay
The amount of glucose uptake in L6 myotubes was an indirect measurement of glucose content in the treated cell medium after 24 h exposure to the test compounds. In Fig. 2B, the amount of glucose uptake was shown as fold-over basal. The positive controls, metformin and insulin, exhibited the uptakes of 1.74-fold and 1.28-fold, respectively, whereas the oxyresveratrol and its derivatives (O22,
O24, and O28) at concentration of 100 µg/ml showed glucose uptake higher than 1.5-fold (1.89, 1.56, 2.06, and 1.92-fold, respectively). Hence, O24, which exhibited the highest glucose uptake activity, and oxyresveratrol were selected for the AMPK expression experiment.

Expression of AMPK α1 and AMPK α2
Activation of AMPK resulted in an increase of glucose uptake in muscle cells, and it was an effective therapeutic strategy for diabetics [25]. The determination of AMPK mRNA expression in L6 myotubes treated with oxyresveratrol and the O24 derivative can reveal the mechanism associated with the AMPK-dependent pathway. In Fig. 3, both the oxyresveratrol and the O24 derivative significantly up-regulated the AMPK α1 and the AMPK α2 expression levels when compared with the control. The transcript expression levels of both AMPK subunits showed a similar pattern with glucose uptake in a dose-dependent manner, except for the 100 µg/ml oxyresveratrol in α2 subunit. It can be explained that the AMPK α1 takes part in the regulation of glucose uptake but not the AMPK α2 [26, 27]. Therefore, these results suggest that the increase in glucose uptake affected by oxyresveratrol and O24 derivative may be correlated with the AMPK signaling pathway.

Docking analysis
The structure-activity relationship of oxyresveratrol and its derivatives on AMPK was investigated by molecular docking analysis. The 3-D structures of oxyresveratrol and the nineteen derivatives binding at the active binding site of 991 (the reference compound) on the AMPK were simulated (Fig. S1) [23]. The lowest binding energy (LBE) values of individual compounds were in the range of −8.33 to −6.20 kcal/mol, while the LBE of 991 was −10.66 kcal/mol (Fig. 4). To assess the high glucose uptake activity compounds in this study, the LBE values of oxyresveratrol, O22, O24, and O28, which respectively were −6.32, −6.20, −7.46, and −6.23 kcal/mol were analyzed. The LBE could be used to predict the binding interaction of compounds or ligands against the binding site. The high glucose uptake activity could be from the carboxyl (−COOH) substituent in R6 position as in O22 and O24. Besides, the hydrogen (−H) substitutes in R1 to R5 positions may contribute in less interaction of ligands to the binding site (higher LBE values in oxyresveratrol and O28) without relating to the glucose uptake activity. In general, the lower the LBE is, the more easily a compound binds to an
The binding energy (kcal/mol) against AMPK for 24 h. Data are expressed as means ± SD, and ** p < 0.05 compared with control by one-way ANOVA, Dunnett t-test.

Fig. 4 Binding energy against AMPK of AMPK activator (991), metformin, oxyresveratrol, and the derivatives.

AMPK mRNA expression. Moreover, the results from molecular docking analysis revealed that the binding energy was not much correlated to the glucose uptake activities. However, the binding energy on the binding site of test compounds can be used to predict the conformation which could be applied to further investigations including structure-activity relationship and structural modification.

Appendix A. Supplementary data

Supplementary data associated with this article can be found at http://dx.doi.org/10.2306/scienceasia1513-1874.2021.107.

Acknowledgements: This work was support by the Program Management Unit for Human Resources and Institutional Development, Research and Innovation (PMU-B) from the Office of National Higher Education Science Research and Innovation Policy Council, Thailand.

REFERENCES

1. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL (2017) Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis 11, 215–225.
2. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013) AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123, 2764–2772.
3. Miglianico M, Nicolaes GAF, Neumann D (2016) Pharmacological targeting of AMP-activated protein kinase and opportunities for computer-aided drug design. J Med Chem 59, 2879–2893.
4. Stapleton D, Mitchellill KL, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, et al (1996) Mammalian AMP-activated protein kinase subfamily. J Biol Chem 271, 611–614.
5. Choonong R, Sermpradit W, Kittisiripanya T, Sritularak B, Putilun W (2019) The contents of bibenzyl derivatives, flavonoids and a phenanthrene in selected Dendrobium spp. and the correlation with their antioxidant activity. ScienceAsia 45, 245–252.
6. Turban S, Stretton C, Drouin O, Green CJ, Watson ML, Gray A, Ross F, Lantier L, et al (2012) Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. *J Biol Chem* **287**, 20088–20099.

7. Breen DM, Sanli T, Giacca A, Tsiani E (2008) Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. *Biochem Biophys Res Commun* **374**, 117–122.

8. Dhanya R, Arya AD, Nisha P, Jayamuthy P (2017) Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line. *Front Pharmacol* **8**, ID 336.

9. Vlavcheski F, Naimi M, Murphy B, Hudlicky T, Tsiani E (2008) Stimulation of muscle cell glucose uptake by resveratrol and activates AMPK. *Molecules* **22**, ID 1669.

10. Chung KO, Kim BY, Kim YR, Chung HY, Park JH, Moon JO (2003) *In-vitro* and *in-vivo* anti-inflammatory effect of oxyresveratrol from *Morus alba* L. *J Pharm Pharmacol* **55**, 1695–1700.

11. Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF (2003) Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. *Nitric Oxide* **9**, 64–76.

12. Likhitwitayawud K, Sritularak B, Benchanak K, Lipipun V, Mathew J, Schinazi RF (2005) Phenolics with antiviral activity from *Milletia erythrocalyx* and *Artocarpus lakoocha*. *Nat Prod Res* **19**, 177–182.

13. Chuanasa T, Phromjai J, Lipipun V, Likhitwitayawud K, Suzuki M, Pramyothin P, Hattori M, Shiraki K (2008) Antiherpes simplex virus (HSV-1) activity of Millettia formosum. *Molecules* **13**, 64–76.

14. Aftab N, Likhitwitayawud K, Vieira A (2010) Comparative antioxidant activities and synergism of resveratrol and oxyresveratrol. *Nat Prod Res* **24**, 1726–1733.

15. Weber JT, Lamont M, Chibrikova L, Fekkes D, Vlug AS, Lorenz P, Kreutzmann P, Slemmer JE (2012) Potential neuroprotective effects of oxyresveratrol against traumatic injury. *Eur J Pharmacol* **680**, 55–62.

16. Chatsumpn N, Chuanasa T, Sritularak B, Lipipun V, Jongbunprasert V, Ruchirawat S, Ploypradith P, Likhitwitayawud K (2016) Oxyresveratrol: structural modification and evaluation of biological activities. *Molecules* **21**, ID 489.

17. Tan HY, Tse IM, Li ET, Wang M (2017) Oxyresveratrol supplementation to C57Bl/6 mice fed with a high-fat diet ameliorates obesity-associated symptoms. *Nutrients* **9**, ID 147.

18. Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, Kim CE, Park KI, et al (2018) Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMPK-activated protein kinase. *Chem Biol Interact* **289**, 66–74.

19. Choi JH, Song NJ, Lee AR, Lee DH, Seo MJ, Kim S, Chang SH, Yang DK, et al (2018) Oxyresveratrol increases energy expenditure through foxo3a-mediated ucpx induction in high-fat-diet-induced obese mice. *Int J Mol Sci* **20**, ID 26.

20. Pan MH, Koh YC, Lee TL, Wang B, Chen WK, Nagabhushanam K, Ho CT (2019) Resveratrol and oxyresveratrol activate thermogenesis via different transcriptional coactivators in high-fat diet-induced obese mice. *J Agric Food Chem* **67**, 13605–13616.

21. Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L (2004) Cell viability assays. In: Markosian S, et al (eds) *Assay Guidance Manual*, Eli Lilly & Company and the National Center for Advancing Translational Sciences, USA, pp 317–342.

22. Inthongkaew P, Chatsumpn N, Supasuteekul C, Kitisiripanya T, Patalun W, Likhitwitayawud K, Sritularak B (2017) Alpha-glucosidase and pancreatic lipase inhibitory activities and glucose uptake stimulatory effect of phenolic compounds from *Dendrobium formosum*. *Rev Bras Farmacogn* **27**, 480–487.

23. Xia B, Sanders MJ, Carmena D, Bright NJ, Haire LE, Underwood E, Patel BR, Heath RB, et al (2013) Structural basis of AMPK regulation by small molecule activators. *Nat Commun* **4**, ID 3017.

24. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem* **16**, 2785–2791.

25. Kjobsted R, Pedersen AJ, Hingst JR, Sabaratnam R, Kjøbsted R, Birk JB, Kristensen JM, Højlund K, Wojtaszewski JP (2016) Intact regulation of the AMPK signaling network in response to exercise and insulin in skeletal muscle of male patients with type 2 diabetes: illumination of AMPK activation in recovery from exercise. *Diabetes* **65**, 1219–1230.

26. Jensen TE, Schjerling P, Violett B, Wojtaszewski JP, Richter EA (2008) AMPK alpha1 activation is required for stimulation of glucose uptake by twitch contraction, but not by H2O2, in mouse skeletal muscle. *PloS One* **3**, e2102.

27. Maarbjerg SJ, Jorgensen SB, Rose AJ, Jeppesen J, Jensen TE, Treebak JT, Birk JB, Schjerling P, et al (2009) Genetic impairment of (alpha)2-AMPK signaling does not reduce muscle glucose uptake during treadmill exercise in mice. *Am J Physiol Endocrinol Metab* **297**, E924–E934.

28. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. *Nature* **510**, 542–546.
Appendix A. Supplementary data

Table S1  Primers used in the real-time PCR reactions.

| Target gene | Forward primers (5′ to 3′) | Reverse primers (5′ to 3′) |
|-------------|-----------------------------|-----------------------------|
| AMPK α1     | ATC CGC AGA GAG ATC CAG AA  | CGT CGA CTC TCC TTT TCG TC  |
| AMPK α2     | TGA GGT GGT GGA GCA GAG G   | TGC TGC CAG TCA AAG AAC CA  |
| GADPH (reference) | GAA GGT CGG TGT GAA CGG AT′ | ACC AGC TTC CCA TTC TCA GC  |

Fig. S1  Simulation of AMPK activator (991), metformin, oxyresveratrol and its derivatives on AMPK, based on 991 compound active binding site.